Stabilised class III viral fusion proteins for more effective immunisation of rabies disease

Applications: Vaccination, rabies, herpes

Class III fusion proteins are expressed on clinically significant viruses and represent important vaccine immunogens. Mutation in the pre-fusion conformation stabilises the proteins, retaining epitopes which stimulate the production of potent neutralising antibodies which are clinically desirable.

Features	Benefits
Stabilises fusion proteins in pre-fusion conformation.	Improves the protein’s efficacy as a vaccine. Stimulates the production of pre-fusion conformation specific neutralising antibodies in humans.
Mutation prevents transformation from pre to post-fusion conformation.	Achieves a similar effect to pre-fusion stabilising mutations used in licensed COVID-19 vaccines. Allows manufacturing of fusion proteins in pre-fusion conformation for vaccination.
To-date only one pre-fusion structure of a Class III fusion protein has been described.	Novel, innovative technology.
Class III fusion proteins of herpesvirus family are known to be targets of the neutralising antibodies.	Can be applied to both rabies and herpes.

Patented & available for:

Licensing
Co-development
Consulting

Request more information
about this technology

Back to Technologies Available

Technologies for License

Stabilised class III viral fusion proteins for more effective immunisation of rabies disease

Ready to get in touch?